Shane Albright

Shane Albright is a partner in Goodwin’s Life Sciences group. He represents life science and technology companies in a wide range of corporate, financing, licensing and commercial matters, with a particular emphasis on complex corporate partnering transactions. He has extensive experience counseling clients on collaborations, strategic alliances, joint ventures, royalty financings, licenses, and key commercial relationships, such as manufacturing and distribution arrangements.

Shane’s clients include companies in the biopharmaceutical, medical device, diagnostics, hardware, software, medical instrumentation, digital health, vaccine, and research reagent spaces, as well as entities that fund or conduct medical research.

• Heidelberg Pharma in its royalty financing agreement with Healthcare Royalty (HCRx), for up to $115 million
• Teva Pharmaceuticals in its collaboration with Sanofi, for an upfront payment of $500 million and up to $1 billion in development and launch milestones, plus a profit share in major markets 
• Avadel Pharmaceuticals in its royalty agreement with RTW Investments, for up to $75 million 
• Entrada Therapeutics in its global collaboration with Vertex Pharmaceuticals focused on Endosomal Escape Vehicle (EEV™) therapeutics, for an upfront payment of $224 million, an equity investment of $26 million, up to $485 million in milestone payments, and tiered royalties
• Medipost in its strategic agreement with OmniaBio, a subsidiary of the Centre for Commercialization of Regenerative Medicine (CCRM)
• Allogene Therapeutics in its global collaboration with Antion Biosciences focused on Antion’s miRNA technology
• Blueprint Medicines in its strategic financing collaborations with Sixth Street and Royalty Pharma, for up to $1.25 billion 
• Syndax Pharmaceutics in its exclusive worldwide collaboration and license agreement with Incyte, for $152 million in upfront cash, up to $450 million in milestone payments, a 50/50 US profit share, and ex-US royalties
• Absci in its research collaboration with Merck involving Absci’s AI-powered Integrated Drug Creation™ Platform, for up to $610 million in upfront fees and milestone payments, as well as research funding and tiered royalties
• Allogene Therapeutics in its formation of a joint venture with Overland Pharmaceuticals to develop and commercialize allogeneic CAR-T therapies in greater China and other Asian countries 
• Proteus Digital Health in its bankruptcy sale to Otsuka America Pharmaceutical
• RTW Investments and Ji Xing Pharmaceuticals in its licensing collaboration and royalty monetization deal with Cytokinetics, for committed capital, funding and sale proceeds of up to $250 million and up to $200 million in milestone payments, plus royalties on future sales in certain Asian countries
• Alnylam Pharmaceuticals in its development and commercialization collaboration with Dicerna Pharmaceuticals focused on investigational RNAi therapeutics
• Alnylam Pharmaceuticals in its $2 billion strategic financing collaboration with Blackstone
• Flexion Therapeutics in its license agreement with HK Tainuo and Jiangsu Tainuo
• Verseau Therapeutics in its strategic collaboration with 3SBio, along with a $15 million investment by 3SBio in Verseau’s Series B financing
• Corbus Pharmaceuticals in its strategic collaboration with Kaken Pharmaceutical, for an upfront payment of $27 million, up to $173 million in milestone payments, and double-digit royalties

Shane was highly ranked by Chambers USA in 2024 for his work in Life Sciences: Corporate/Commercial in California.

In recognition of his outstanding transactional work, Shane is recommended as a leading transactional lawyer by IAM Patent 1000 and has been featured as a “Life Sciences Star” in LMG Life Sciences.

Shane is a frequent speaker on issues relating to licensing and corporate partnering.